How many employees does NeoGenomics, Inc. have?

NeoGenomics, Inc. reported 2,500 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 17, 2026. That is up 13.6% from a year earlier.

What is NeoGenomics, Inc.'s revenue per employee?

NeoGenomics, Inc. brought in $727M of revenue in fiscal Dec 2025, which is $291K per employee. That ranks 16 of 26 companies we track in Medical - Diagnostics & Research, where the median is $366K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

NeoGenomics, Inc. employees and revenue per employee

NEO · Medical - Diagnostics & Research · $420M market cap

NeoGenomics, Inc. had 2,500 employees at the end of fiscal Dec 2025, up 13.6% from a year earlier. Revenue for the year was $727M, up 10.1% from a year earlier, or $291K per employee. Headcount grew faster than revenue.

Employees

2,500

+13.6% YoY

Revenue

$727M

+10.1% YoY

Revenue / employee

$291K

Peer median $366K

Rank in industry

16 of 26

Medical - Diagnostics & Research

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

NEO employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	2,500	$727M	$291K	+13.6%	+10.1%
Dec 2024	2,200	$661M	$300K	+4.8%	+11.6%
Dec 2023	2,100	$592M	$282K	+0.0%	+16.1%
Dec 2022	2,100	$510M	$243K	+5.0%	+5.2%
Dec 2021	2,000	$484M	$242K	+17.6%	+9.0%
Dec 2020	1,700	$444M	$261K	+0.0%	+8.7%
Dec 2019	1,700	$409M	$240K	+13.3%	+47.7%
Dec 2018	1,500	$277M	$184K	+50.0%	+15.2%
Dec 2017	1,000	$240M	$240K	+6.6%	-1.6%
Dec 2016	938	$244M	$260K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

NeoGenomics, Inc. against similar companies

The closest industry peers by revenue, from Medical - Diagnostics & Research.

Company	Employees	Revenue	Revenue / employee	Shape
VCYT Veracyte, Inc.	755	$517M	$685K	Leaner
CDNA CareDx, Inc	761	$380M	$499K	Hiring ahead
BLLN BillionToOne, Inc.	713	$305M	$428K	—
GH Guardant Health, Inc.	2,490	$982M	$394K	Efficient growth
CSTL Castle Biosciences, Inc.	883	$344M	$390K	Hiring ahead
SHC Sotera Health Company	3,000	$1.16B	$388K	Leaner
WGS GeneDx Holdings Corp.	1,300	$428M	$329K	Efficient growth
NEO NeoGenomics, Inc.	2,500	$727M	$291K	Hiring ahead
FLGT Fulgent Genetics, Inc.	1,300	$323M	$248K	Hiring ahead

Every Healthcare company

Questions about NeoGenomics, Inc.

How many employees does NeoGenomics, Inc. have?: NeoGenomics, Inc. reported 2,500 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 17, 2026. That is up 13.6% from a year earlier.
What is NeoGenomics, Inc.'s revenue per employee?: NeoGenomics, Inc. brought in $727M of revenue in fiscal Dec 2025, which is $291K per employee. That ranks 16 of 26 companies we track in Medical - Diagnostics & Research, where the median is $366K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare NEO with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in NeoGenomics, Inc.'s annual reports (Form 10-K), latest filed February 17, 2026. This is data, not a recommendation to buy or sell NEO.